drugset / Trial / NCT02583542
A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers
Phase 1/2
Unknown
118 enrolled
Queen Mary University of London
AstraZeneca · collabCancer Research UK · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Open-label, multicentre phase Ib/IIa study of AZD2014 administered with selumetinib. There are two parts to this study: a dose-escalation part in treatment-refractory advanced solid tumours and a subsequent separate expansion cohort part for TNBC, squamous cell lung cancers, non-squamous cell lung cancers with KRAS mutations and non-squamous cell lung cancers with wild-type KRAS
Timeline
- Start
- 2015-06
- Primary completion
- 2020-03
- Completion
- 2020-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Selumetinib | Small molecule | — | Oral |
| Subject | Vistusertib | Small molecule | — | — |